COLL vs EXAS · P/E 17, rev $181.9M vs rev $2.76B
Collegium Pharmaceutical Inc (COLL) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the COLL and EXAS stock pages for the full models.
Not investment advice.